Evidence map›Paper›PMID 25512432›Full record

ArticleTobacco control2016

The importance of product definitions in US e-cigarette laws and regulations.

Lauren K Lempert, Rachel Grana, Stanton A Glantz

Abstract read
In one paragraph

Article in Tobacco control, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Overview of Electronic Nicotine Delivery Systems: A Systematic Review.American journal of preventive medicine · 2017
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Insights in Public Health: Formative Factors for a Statewide Tobacco Control Advocacy Infrastructure: Insights from Hawai'i.Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health · 2019
    Article
  16. Article
  17. Article
  18. Differences in Adolescent E-cigarette and Cigarette Prevalence in Two Policy Environments: South Korea and the United States.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2018
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lauren K LempertCenter for Tobacco Control Research and Education, Cardiovascular Research Institute, University of California San Francisco, San Francisco, California, USA.
Rachel GranaCenter for Tobacco Control Research and Education, Cardiovascular Research Institute, University of California San Francisco, San Francisco, California, USA.
Stanton A GlantzCenter for Tobacco Control Research and Education, Cardiovascular Research Institute, University of California San Francisco, San Francisco, California, USA Division of Cardiology, Department of Medicine, University of California San Francisco, San Francisco, California, USA Philip R. Lee Institute for Health Policy Studies, University of California San Francisco, San Francisco, California, USA.

Funding

TOBACCO ADVOCACY AT THE STATE LEVELR01CA061021 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GLANTZ, STANTON ARNOLD · 1994 to 2015
$7.4M
Understanding Smokeless Tobacco MarketingR01CA141661 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LING, PAMELA MAY · 2009 to 2019
$5.4M
NCI NIH HHS CA060121NCI NIH HHS CA141661NCI NIH HHS R01 CA061021NCI NIH HHS R01 CA141661
6 · The paper itself

Abstract

backgroundHow electronic cigarettes and similar products (e-cigarettes) are defined affects how they are regulated, particularly whether existing laws for cigarettes apply, including sales and marketing, youth access, smoke-free and taxation laws.

methodsWe examined the text of 46 bills that define e-cigarettes enacted in 40 states and characterised how e-cigarettes and similar products were defined.

resultsStates enact laws creating new product categories for e-cigarettes separate from the 'tobacco product' category (eg, 'alternative nicotine product,' 'vapour product,' 'electronic nicotine device'), with four states explicitly excluding e-cigarettes from 'tobacco products.' Twenty-eight states do not include e-cigarettes in their definitions of 'tobacco products' or 'smoking,' eight include e-cigarettes as 'tobacco products,' three include e-cigarettes in 'smoking.' Sixteen states' definitions of e-cigarettes require nicotine, and five states pre-empt more stringent local laws. Tobacco and e-cigarette industry representatives tried to shape laws that benefit their interests.

conclusionsDefinitions separating e-cigarettes from other tobacco products are common. Similar to past 'Trojan horse' policies, e-cigarette policies that initially appear to restrict sales (eg, limit youth access) may actually undermine regulation if they establish local pre-emption or create definitions that divide e-cigarettes from other tobacco products. Comparable issues are raised by the European Union Tobacco Products Directive and e-cigarette regulations in other countries. Policymakers should carefully draft legislation with definitions of e-cigarettes that broadly define the products, do not require nicotine or tobacco, do not pre-empt stronger regulations and explicitly include e-cigarettes in smoke-free and taxation laws.

Indexed as

Government RegulationLocal GovernmentSmoking PreventionTerminology as TopicElectronic Nicotine Delivery SystemsHumansPolicy MakingSmokingSmoking CessationTobacco ProductsUnited StatesVapingElectronic nicotine delivery devicesNon-cigarette tobacco productsPublic policyTaxationTobacco industry

Identifiers

PMID25512432
PMCPMC4466213

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.